#South Korea #Seoul #Seegene #CURECA™ #STAgora

Seegene Unveils Groundbreaking CURECA™ PCR System at ADLM 2025

Seegene, a recognized leader in molecular diagnostics, is set to present its pioneering PCR automation system, CURECA™, during the upcoming ADLM 2025 conference held in Chicago from July 28 to 31. This fully automated system promises to redefine standards in PCR testing by ensuring total automation across the entire process, thereby minimizing human intervention and potential errors.

A New Era of Automation

The CURECA™ system signifies a monumental leap in the realm of diagnostic testing. It encompasses every step of the PCR testing workflow, from sample storage, pre-treatment, and nucleic acid extraction to amplification and result analysis. The automation ensures that tests run continuously, 24/7, which not only enhances efficiency but also significantly improves the reliability of results, a crucial aspect in clinical diagnostics.

Traditionally, pre-treatment phases in PCR testing have been a bottleneck, often fraught with challenges, particularly when handling diverse sample types. The innovative design of CURECA™ addresses issues predominantly arising in manual pre-treatment tasks, which are labor-intensive and susceptible to variability due to differing technician skill levels. This is particularly true for stool samples, which have proven especially challenging due to their viscosity and particulate matter. CURECA™ overcomes these hurdles, markedly reducing the labor needed while improving testing throughput and overall operational efficiency.

Flexible and Modular Design

One of the standout features of CURECA™ is its modular architecture, which allows for easy configuration based on the specific needs and layout of different laboratories. Beyond PCR diagnostics, the system's prep module extends its applications to clinical chemistry and immunoassay processes, representing a significant advancement towards larger automation objectives across various diagnostic sectors.

STAgora™: Empowering Data-Driven Diagnostics

Accompanying the unveiling of CURECA™, Seegene will also launch STAgora™, a robust statistical platform that aggregates real-time PCR diagnostic data. This analytic tool enables healthcare providers to gain insights into regional infection trends and hospital positivity rates, which are pivotal in tailoring precise treatment for patients. Features like comparative analysis can greatly enhance clinical decision-making, ensuring strategies are informed by comprehensive data.

By integrating test results with broader epidemiological data, STAgora™ supports clinicians in adapting their approaches not just at a personal patient level but also across community populations, paving the way for precision medicine.

Collaborative Future and Global Impact

As Seegene showcases its innovations at ADLM 2025, it aims to facilitate a broader adoption of CURECA™ and STAgora™ through pilot partnerships. This collaborative approach will ensure that healthcare providers globally can harness these advanced technologies, ultimately enhancing diagnostic capabilities.

Earlier in the year, CURECA™ attracted significant attention at the ESCMID Global 2025 conference, highlighting its potential. To bolster its research and development as well as manufacturing capabilities in the U.S., Seegene has established local subsidiaries, reinforcing its commitment to innovation.

Daniel Shin, the Executive Vice President at Seegene, aptly summarizes the impact of their new offerings, “CURECA™ and STAgora™ are not mere products; they embody a new global standard for diagnostics that will substantially enhance clinical practices worldwide.”

In summarizing its technological advancements, Seegene reminds the medical community that these offerings are still in pre-commercialization phases and are presented as platforms for future innovations in diagnostic methods.

About Seegene

With over two decades of specialized expertise in research and development, manufacturing, and business operations focused on syndromic real-time PCR technologies, Seegene has been at the forefront of rapid diagnostics, especially during urgent public health crises like the COVID-19 pandemic. The company has successfully distributed millions of tests globally, proving its commitment to advancing public health.

For more information, visit Seegene.com and connect via LinkedIn.